Newsroom

NEWSROOM

March 23, 2021

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

March 4, 2021 Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.
March 23, 2021

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

February 4, 2021 Represents second approved indication for Restylane Defyne in U.S. 
November 19, 2020

Galderma launches Dysport® in China for treatment of glabellar lines

November 18, 2020 Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.
November 19, 2020

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

November 17, 2020 Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®
November 6, 2020

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

October 9, 2020 Phase 3 READY program of its proprietary, liquid formulation of an investigational botulinum toxin is fully enrolled.
October 29, 2020

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

April 22, 2020 First approval for a class III medical device for improved skin appearance in China. 

October 29, 2020

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*

April 15, 2020 Business-building webinars to support local Aesthetic practices. Expert injector techniques by GAIN faculty.